SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
RecoveryResearch-onlyVendors pending
Research-onlyVendors pendingFacts verified · 2026-05-25

BPC-157 (oral tablets)

Also known as BPC-157 (Tablets), bepecin, pl 14736, body protection compound 157, gastric pentadecapeptide · Wikipedia

BPC-157 (oral tablet form) delivers the same 15-amino-acid pentadecapeptide (Body Protection Compound-157, PL 14736) as the injectable product, marketed primarily for gut healing and systemic recovery. The 'gastric-stable' / 'orally active' claim is the central marketing point but is not validated by human pharmacokinetic data - the limited PK work is in rats and dogs (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794587/), and only a handful of pilot human studies of injectable BPC-157 have been published. The FDA classified BPC-157 as a Category 2 (significant safety risk) bulk drug substance in 2023, effectively prohibiting its use in 503A compounded preparations; a PCAC re-review is scheduled for July 2026. Also known as: Bepecin; PL 14736; Body Protection Compound 157.

—

best

price

—

per

mg

—

vendors

tracked

Research-only

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Oral BPC-157 is intended to deliver the same pentadecapeptide as the injectable form. Proposed mechanisms (characterized almost entirely in rodent models, predominantly from the Sikiric group in Zagreb) include VEGFR2-Akt-eNOS-mediated angiogenesis, modulation of the nitric-oxide system, growth-factor and focal-adhesion signaling (FAK-paxillin, EGR-1) in fibroblasts and tendon cells, induction of collagen synthesis, and stabilization of the gut-brain axis via dopaminergic/serotonergic effects (https://pmc.

Oral BPC-157 is intended to deliver the same pentadecapeptide as the injectable form. Proposed mechanisms (characterized almost entirely in rodent models, predominantly from the Sikiric group in Zagreb) include VEGFR2-Akt-eNOS-mediated angiogenesis, modulation of the nitric-oxide system, growth-factor and focal-adhesion signaling (FAK-paxillin, EGR-1) in fibroblasts and tendon cells, induction of collagen synthesis, and stabilization of the gut-brain axis via dopaminergic/serotonergic effects (https://pmc.ncbi.nlm.nih.gov/articles/PMC11053547/). Vendor literature claims gastric-juice stability based on the molecule's putative origin from a human gastric protein, and rodent oral dosing reproduces some healing effects, particularly in the GI tract. However, human oral bioavailability for systemic targets is uncharacterized and the most defensible mechanism for oral capsules is local action on the GI mucosa, not systemic 'whole-body' healing.

Pharmacokinetic properties

Half-life

unknown for oral; injectable estimated 4-6 hours

Routes

oral

Bioavailability

Oral bioavailability in humans is unknown and likely low for systemic targets. Local action in the GI lumen and gut wall is plausible and best-supported by data; systemic 'whole-body' effects from oral capsules are extrapolated and not validated by PK studies.

Amino-acid sequence

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Use & research dosing

Injury RecoveryJoint HealthRecovery

There is no FDA-approved human dose. Self-experimentation protocols commonly report 250-500 mcg orally one to three times daily, frequently for GI complaints (IBD, ulcers, leaky-gut symptoms) where local luminal action is plausible even without systemic absorption. Rodent oral PK shows plasma BPC-157 returns to baseline within 24 hours (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794587/). No human oral bioavailability or dose-finding data exist; dosing is extrapolated from injectable protocols and rodent allometry, not from validated human PK.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

The 'stomach-stable / orally bioavailable' claim is the central marketing premise of oral BPC-157 tablets but is not validated by human pharmacokinetic data. Rodent oral dosing does reproduce some GI healing effects (consistent with local mucosal action), but systemic 'whole-body' bioactivity from oral capsules is extrapolated rather than measured. Most realistic use case for oral tablets is gut-localized indications (IBD, GERD, ulcers) where systemic absorption is not required. FDA's 2023 Category 2 classification means compounding pharmacies cannot legally include BPC-157; the July 2026 PCAC review may revisit this.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • No human pharmacokinetic, bioavailability, or efficacy data for the oral formulation
  • FDA Category 2 (significant safety risk) bulk substance for 503A compounding (Sept 2023); PCAC re-review scheduled July 23-24, 2026 (https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026)
  • Pro-angiogenic activity raises a theoretical concern in active or suspected malignancy
  • WADA-prohibited in athletic competition (S0 non-approved substances)
  • Capsule purity, content uniformity, and dose accuracy from research-chemical vendors are unverified
  • Vast majority of efficacy data come from a single research group (Sikiric, Zagreb) - limited independent replication (https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/)
  • Long-term toxicology, immunogenicity, reproductive, and developmental effects unknown
  • Avoid in pregnancy and lactation due to absent safety data
  • Oral tablet excipients and enteric coating quality variable across vendors

Research foundation

The papers behind the page.

  1. [01]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794587/
  2. [02]https://pmc.ncbi.nlm.nih.gov/articles/PMC11053547/
  3. [03]https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
  4. [04]https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

Facts verified

2026-05-25

Confidence

low

What this means

  • oral human PK unvalidated
  • FDA 503A Category 2 (significant safety risk)
  • >80% preclinical data from single research group

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.

BPC-157 (oral tablets) · SavePeptides